Insulet reported 29.9% year-over-year revenue growth in the most recent quarter, with sales totaling $521.7 million driven by accelerating adoption of its Omnipod 5 tubeless insulin pump. The company’s gross margin expanded by 180 basis points to 64.3% as manufacturing efficiencies scaled and pod utilization increased. Insulet delivered adjusted earnings per share of $1.24, beating consensus by $0.11, while posting a net margin of 9.76% and a 24.36% return on equity. Management highlighted that Omnipod 5 units accounted for more than 40% of total pod volume during the quarter, underscoring strong end-market demand and improving unit economics.

Braun Stacey Associates initiated a position of 53,952 shares in Insulet during the third quarter, representing a $16.7 million investment and roughly 0.08% of shares outstanding. Vanguard increased its stake by 0.5%, adding 39,403 shares to reach 8,708,355 shares, while Geode Capital Management boosted its holding by 3.1% to 1,927,543 shares. Norges Bank established a new position valued at $324.7 million, and Federated Hermes added 90,494 shares (a 14.3% increase). Charles Schwab Investment Management also raised its exposure by 1.0%, reflecting growing confidence from major asset managers in Insulet’s growth trajectory.

Following the quarterly beat, analysts have revised 2024 earnings estimates higher, with consensus now pointing to $3.92 per share for the full year. Raymond James raised its target by 5.1%, Wolfe Research by 7.1%, and JPMorgan Chase upgraded to overweight after increasing its projection by 22%. Of the 25 analysts covering the name, one assigns a strong-buy, 22 a buy and two a hold, yielding an average recommendation of moderate buy. This upward revision cycle reflects confidence in sustained Omnipod 5 adoption, margin accretion and Insulet’s ability to capture additional market share in the growing insulin pump segment.